logo-loader

Cellect Biotechnology shares skyrocket as first blood cancer patient treated in clinical trial

Last updated: 15:00 08 Feb 2017 GMT, First published: 10:00 08 Feb 2017 GMT

shutterstock_139099559
The trial will test stem cells transplanted from a matched donor related to the patient.

Shares in Cellect Biotechnology Ltd (NASDAQ:APOP) soared almost 50% higher in New York as it told investors it had treated the first blood cancer patient in its recently started phase I/II trial of its stem cell technology ApoGraft.

The firm's technology means it can select stem cells from any given tissue for any clinical indication.

This trial in Israel is intended to assess the Cellect ApoGraft process which is designed to prevent Graft-versus-Host Disease (GvHD) -  a common complication associated with stem cell transplant in which the transplanted immune cells attack the recipient's cells.

It will test stem cells transplanted from a matched donor related to the patient.

GvHD is a life-threatening condition occurring in up to 50% of stem cell transplants.

Cellect chief executive Shai Yarkoni said: "Enrolling our first cancer patient to be treated using our groundbreaking method is a critical milestone for millions of patients worldwide.

"ApoGraft has been proven to be effective in assisting successful stem cells transplants and preventing GvHD during our animal studies.  I am excited with prospects of Cellect becoming a key contributor to the fast-growing market for stem cells based products enabling 21st century regenerative medicine."

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

1 hour, 31 minutes ago